About AP-3 complex subunit beta-2
AP-3 complex subunit beta-2 (AP3B2) is a protein
from Homo sapiens identified by UniProt accession
Q13367, 1082 residues long.
MolForge cross-references it against 0 known binders and
281 disease associations.
Target properties
| Protein name | AP-3 complex subunit beta-2 |
|---|
| UniProt accession | Q13367 |
|---|
| Gene | AP3B2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1082 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (281)
Diseases linked to this target (Open Targets).
- developmental and epileptic encephalopathy, 48 · score 0.72
- developmental and epileptic encephalopathy · score 0.55
- undetermined early-onset epileptic encephalopathy · score 0.37
- Epileptic encephalopathy · score 0.33
- age at first sexual intercourse measurement · score 0.31
- cognitive function measurement · score 0.29
- self reported educational attainment · score 0.29
- Intellectual disability · score 0.27
- Seizure · score 0.27
- mathematical ability · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q13367-F1 | alphafold | PREDICTED | 74.88 | — |
Amino-acid sequence (1082 residues)
MSAAPAYSED KGGSAGPGEP EYGHDPASGG IFSSDYKRHD DLKEMLDTNK DSLKLEAMKR IVAMIARGKN ASDLFPAVVK NVACKNIEVK KLVYVYLVRY AEEQQDLALL SISTFQRGLK DPNQLIRASA LRVLSSIRVP IIVPIMMLAI KEAASDMSPY VRKTAAHAIP KLYSLDSDQK DQLIEVIEKL LADKTTLVAG SVVMAFEEVC PERIDLIHKN YRKLCNLLID VEEWGQVVII SMLTRYARTQ FLSPTQNESL LEENAEKAFY GSEEDEAKGA GSEETAAAAA PSRKPYVMDP DHRLLLRNTK PLLQSRSAAV VMAVAQLYFH LAPKAEVGVI AKALVRLLRS HSEVQYVVLQ NVATMSIKRR GMFEPYLKSF YIRSTDPTQI KILKLEVLTN LANETNIPTV LREFQTYIRS MDKDFVAATI QAIGRCATNI GRVRDTCLNG LVQLLSNRDE LVVAESVVVI KKLLQMQPAQ HGEIIKHLAK LTDNIQVPMA RASILWLIGE YCEHVPRIAP DVLRKMAKSF TAEEDIVKLQ VINLAAKLYL TNSKQTKLLT QYVLSLAKYD QNYDIRDRAR FTRQLIVPSE QGGALSRHAK KLFLAPKPAP VLESSFKDRD HFQLGSLSHL LNAKATGYQE LPDWPEEAPD PSVRNVEVPE WTKCSNREKR KEKEKPFYSD SEGESGPTES ADSDPESESE SDSKSSSESG SGESSSESDN EDQDEDEEKG RGSESEQSEE DGKRKTKKKV PERKGEASSS DEGSDSSSSS SESEMTSESE EEQLEPASWS RKTPPSSKSA PATKEISLLD LEDFTPPSVQ PVSPPAIVST SLAADLEGLT LTDSTLVPSL LSPVSGVGRQ ELLHRVAGEG LAVDYTFSRQ PFSGDPHMVS VHIHFSNSSD TPIKGLHVGT PKLPAGISIQ EFPEIESLAP GESATAVMGI NFCDSTQAAN FQLCTQTRQF YVSIQPPVGE LMAPVFMSEN EFKKEQGKLM GMNEITEKLM LPDTCRSDHI VVQKVTATAN LGRVPCGTSD EYRFAGRTLT GGSLVLLTLD ARPAGAAQLT VNSEKMVIGT MLVKDVIQAL TQ
Explore AP-3 complex subunit beta-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets